Relay and iTeos join IPO deluge while Akouos and Fusion decide they can earn more
They just don’t. Stop. Coming.
If biotechs have learned anything during the pandemic economy, it’s that investors have become eager to jump in to buy …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
